COVID-19 Archive:ワクチン｜株式会社Smart119｜新型コロナウィルス感染症関連論文アーカイブ

Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273(JAMA 2021.8.30)

2021.07.05

Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 (Nature 2021.6.30)

2021.06.11

Adjunct Immune Globulin for Vaccine-Induced Thrombotic Thrombocytopenia (NEJM 2021.6.9)

2021.05.13

BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants (NEJM 2021.5.12)

2021.05.11

Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers (JAMA 2021.5.6)

2021.05.10

US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021 (JAMA 2021.4.30)

2021.04.26

Acute Allergic Reactions to mRNA COVID-19 Vaccines (JAMA 2021.3.8)

2021.04.15

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination (NEJM 2021.4.9)

2021.04.15

SARS-CoV-2-Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women (JAMA 2021.4.12)

2021.04.12

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination (NEJM 2021.4.9)

2021.04.06

SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera (Cell 2021.3.20)

2021.03.16

Covid-19 Vaccine Resource Center(NEJM 2021.4.2)②

2021.03.16

Covid-19 Vaccine Resource Center （NEJM 2021.4.2)①

2021.03.05

Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2 (JAMA 2021.3.3)

2021.03.02

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting (NEJM 2021.2.24)

2021.03.02

The Johnson & Johnson Vaccine for COVID-19 (JAMA 2021.3.1)

2021.02.24

COVID-19 Archive: ワクチン

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months (NEJM 2021.10.6)

Spontaneous Abortion Following COVID-19 Vaccination During Pregnancy (JAMA 2021.9.8)

Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce (NEJM 2021.9.1)

Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273(JAMA 2021.8.30)

Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 (Nature 2021.6.30)

Adjunct Immune Globulin for Vaccine-Induced Thrombotic Thrombocytopenia (NEJM 2021.6.9)

BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants (NEJM 2021.5.12)

Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers (JAMA 2021.5.6)

US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021 (JAMA 2021.4.30)

Acute Allergic Reactions to mRNA COVID-19 Vaccines (JAMA 2021.3.8)

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination (NEJM 2021.4.9)

SARS-CoV-2-Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women (JAMA 2021.4.12)

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination (NEJM 2021.4.9)

SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera (Cell 2021.3.20)

Covid-19 Vaccine Resource Center(NEJM 2021.4.2)②

Covid-19 Vaccine Resource Center （NEJM 2021.4.2)①

Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2 (JAMA 2021.3.3)

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting (NEJM 2021.2.24)

The Johnson & Johnson Vaccine for COVID-19 (JAMA 2021.3.1)

How soon will COVID-19 vaccines return life to normal? (Science 2021.2.16)